🏛️ Verified NIH Record • Updated 2026-06-15
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis (NCT05556096)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Alexion Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Who can join: Review the eligibility criteria below.
Location: Research Site — Orange, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (132 Sites)
Showing the first 25 of 132 sites.
- Research Site — Orange, California
- Research Site — Fort Collins, Colorado
- Research Site — Washington D.C., District of Columbia
- Research Site — Bradenton, Florida
- Research Site — Maitland, Florida
- Research Site — Tampa, Florida
- Research Site — Augusta, Georgia
- Research Site — Gainesville, Georgia
- Research Site — Savannah, Georgia
- Research Site — Springfield, Illinois
- Research Site — Kansas City, Kansas
- Research Site — Lexington, Kentucky
- Research Site — Detroit, Michigan
- Research Site — East Lansing, Michigan
- Research Site — Las Vegas, Nevada
- Research Site — Patchogue, New York
- Research Site — Rochester, New York
- Research Site — Syracuse, New York
- Research Site — Chapel Hill, North Carolina
- Research Site — North Charleston, South Carolina
- Research Site — Houston, Texas
- Research Site — Richmond, Virginia
- Research Site — Morgantown, West Virginia
- Research Site — CABA,
- Research Site — Ciudad de Buenos Aires,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis — Scottsdale, Arizona
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — Scottsdale, Arizona
- Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis — Los Angeles, California
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis — Phoenix, Arizona
- A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Scottsdale, Arizona
Explore by condition: All Generalized Myasthenia Gravis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.